Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess et al. · Journal of Clinical Oncology · 2008 · 2.9K citations · Full text

Medicine, Oncology, Breast Oncology +16

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Breast Oncology +12

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Daniel P. Silver, Andrea L. Richardson, Aron C. Eklund et al. · Journal of Clinical Oncology · 2010 · 984 citations · Full text

Medicine, Oncology, Pharmacology +16

Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations

Sunil R. Lakhani, J Jacquemier, J P Sloane et al. · JNCI Journal of the National Cancer Institute · 1998 · 707 citations · Full text

Medicine, Oncology, Pathology +17

The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin

Anamitra Bhattacharyya, Uy Ear, Beverly H. Koller et al. · Journal of Biological Chemistry · 2000 · 588 citations · Full text

Life Sciences, Genetics, Oncology +17